Medidata Solutions, a global leader in electronic data capture
(EDC), management and reporting solutions, today announced the
company's 25th quarter of consecutive growth and the largest revenue
quarter in company history. Medidata made impressive gains with a 121
percent year over year revenue growth. Ten new customers signed within
the quarter to implement 16 trials spanning Phases I through IV, and
10 existing customers signed follow-on contracts to continue using
Medidata Rave(R) for multiple studies.
Medidata continues to expand through direct wins from life science
sponsors and its growing relationships with contract research
organizations (CROs). Medidata's ASPire to Win(TM) partner program
enables CROs to meet sponsor demand for Medidata Rave and offer the
platform in-house by building and deploying studies with Rave
certified resources.
Other key accomplishments in Q1 include:
-- Introduction of Rave 5.6 - Building on Medidata Rave's
multiple language capabilities and ease-of-use, Medidata Rave
5.6 offers broad EDC and CDMS functionality allowing sponsors
to experience increased efficiencies and reduced risk in
handling any size or phase study within a single, scalable
system.
-- Orion Corporation customer win - Finland-based pharmaceutical
company standardized on Medidata Rave as its global EDC
management and reporting solution, with the goal of managing
all trials with Medidata Rave within the next few years.
-- Fast Track partnership - Medidata entered into a multi-year
agreement to integrate Fast Track's TrialSpace Designer(R)
(TSD) study design software with Medidata Rave for faster
trial start-up.
-- ICON two-year milestone - At the second anniversary of
Medidata's partnership with leading CRO ICON, the firms
announced that Medidata Rave had been selected by 19 companies
for 37 clinical trials across Phases I-IV, in a range of
therapeutic areas.
-- 18 percent staff increase - Medidata continued to expand in
the U.S., Europe and Japan and added Dr. Hugh P. Levaux, Ph.D.
as vice president of product strategy, to drive the overall
definition and management of Medidata's product offerings.
-- Global speaking engagements - Medidata executives delivered
presentations at industry events in Q1, including the 5th
Annual Phase IV Clinical Trials Conference, Clinical Trials
Congress, DIA's 10th Annual Workshop in Japan for Clinical
Data Management and International Symposium on Clinical
Trials.
"Our team's ability to listen and respond to the market with new
product developments, form key partnerships and expand on
relationships with CROs was critical to reaching the largest revenue
quarter in our company's history," said Tarek Sherif, CEO of Medidata
Solutions. "This milestone speaks to the momentum we have built with
Medidata Rave, which, with broad CDMS capabilities, is viewed as the
industry standard for EDC and clinical data management. As pleased as
we are with earning the confidence of our new customers, we also value
the continued roll-out of studies by customers who have signed
enterprise-wide deployments. As sponsors and CROs continue to make
investments in our technology, we look forward to announcing further
achievements and expansion throughout the year."
About Medidata Solutions Worldwide
Medidata Solutions helps the world's leading pharmaceutical,
biotechnology, medical device and research organizations maximize the
value of their clinical research investments. Innovative process
design, technology and services streamline clinical trials by
providing early visibility to reliable clinical data - the lifeblood
of every research organization. Working with companies and
institutions both large and small, Medidata Solutions helps clinical
researchers safely accelerate the process of bringing life-enhancing
treatments to market - on six continents and in more than 80
countries. Medidata Solutions brings significant value to its broad
client base with deep clinical experience and expertise in more than
20 therapeutic areas, projects in Phase I, II, III, IV, registries and
surveillance, and studies with thousands of investigators and
tens-of-thousands of subjects. For more information, please visit
www.mdsol.com.
